Medipure Holdings Inc.
CNSX : MDH

Medipure Holdings Inc.

February 17, 2015 06:30 ET

Medipure Announces Development of First Proprietary Cannabinoid Formulations

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 17, 2015) -

THIS PRESS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES, AND SHOULD NOT BE DISSEMINATED WITHIN THE U.S.

Medipure Holdings Inc. ("Medipure," or the "Company") (CSE:MDH) is pleased to announce that it has commenced the development of MP-10X and MP-20X, the Company's first proprietary cannabinoid formulations.

Research currently being undertaken on both the MP-10X and MP-20X formulations will not only allow Medipure to identify the molecular mechanisms of action within these formulations, but also generate the necessary pharmacological evidence for dosage, safety, and efficacy. This information will enable the Company to make informed decisions regarding which formulations are ideally suited for advancement towards clinical trials.

Medipure's MP-10X formulations are intended for pain management, while the MP-20X formulations are intended for the treatment of anxiety. An overview of these formulations is presented below.

About MP-10X (Pain Management)

Medipure is currently developing its MP-10X formulations through pilot studies with cancer patients. This research will develop specific cannabinoid molecule-based pharmaceuticals for pain management. Many types of cancers, as well as the side effects of cancer treatments (e.g., radiation, chemotherapy, surgery), manifest in various forms of acute and chronic nociceptive and neuropathic pain. Nociceptive pain is pain caused by damaged tissue. This includes chronic pain such as visceral and deep somatic pain. Nociceptive pain may be caused by injury or associated with carcinoma/sarcoma. Neuropathic pain is pain caused by damaged nerves, and can result in the feeling of pain from normally non-painful stimuli. Neuropathic pain may be caused by spinal cord injury, multiple sclerosis, diabetes, or cancer.

Cannabinoids are capable of targeting a broad range of pharmacological mechanisms of pain, and many of these cannabinoids do not have the psychotropic effects typically associated with cannabis. Furthermore, many current treatments of pain (e.g., opiates) have significant issues related to patient tolerability and dependency, in addition to other negative side effects.

Medipure's MP-10X sublingual/transmucosal formulations are developed to target pain types through the activation of specific molecular mechanisms. These formulations are delivered sublingually to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit.

About MP-20X (Anxiety)

Medipure is currently developing its MP-20X formulations through pilot studies with cancer patients. This research will develop specific cannabinoid molecule-based pharmaceuticals for the treatment of anxiety. Those who have been diagnosed with cancer can experience a wide spectrum of anxiety disorders. Anxiety is a result of a combination of biological, psychological, and other individual factors. Neurochemical imbalances in g-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, and other neurotransmitter pathways in the brain can contribute to the development of anxiety.

Medipure's goal is to avoid issues related to dependency and tolerance that exist in currently available anxiolytic medications, while ensuring optimal product safety and efficacy.

Medipure's MP-20X sublingual/transmucosal formulations are developed to target pain types through the activation of specific molecular mechanisms. These formulations are delivered sublingually to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit.

About Medipure Holdings Inc.

Medipure is developing an extensive network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. Medipure will attempt to bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of our products through rapid cost- effective product development, addressing market needs, and establishing strategic partnerships. Although Medipure has applied to Health Canada for a license to produce and distribute medical marihuana under the Marihuana for Medical Purposes Regulations, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy the securities in any jurisdiction. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act. This press release is not intended for distribution to U.S. newswire services, and should not be disseminated within the U.S.

Contact Information